Global Ophthalmology Drugs Market OutlookThe global ophthalmology drugs market is forecasted to expand at a CAGR of nearly 8% over the next several years, driven by the rising burden of vision ...

In diabetic macular edema, faricimab can improve visual acuity for treatment-naïve eyes or sustain vision for those ...

The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and emerging treatment paradigms.

Explore the cost-effectiveness of ranibizumab biosimilars versus aflibercept in treating AMD and DME, revealing significant ...

Regeneron Pharmaceuticals, Inc. REGN announced a collaboration agreement with private company Tessera Therapeutics, Inc. for ...

Shares of Regeneron Pharmaceuticals REGN have gained 21.5% year to date compared with the industry’s growth of 10.2%. The ...

India’s soaring diabetes burden is fuelling a silent surge in diabetic retinopathy. Firstpost brings out a doctor’s ...

Kamuvudines are a new class of drugs that are derived from the anti-HIV nucleoside reverse transcriptase inhibitors. They are designed to inhibit the inflammasome, part of the innate immune system ...

First patient randomized into HELIOS-3, which along with HELIOS-2 form the basis of AXPAXLI's registrational program in non-proliferative diabetic retinopathy (NPDR) HELIOS-2 and HELIOS-3 are global ...

Detailed price information for Clearside Biomedical Inc (CLSD-Q) from The Globe and Mail including charting and trades.

Please provide your email address to receive an email when new articles are posted on . The decision is supported by positive visual acuity gains found in the phase 3 QUASAR trial. This is the fourth ...

The FDA also approved an every 4 week dosing regimen across all approved indications for patients who may not maintain a response on extended dosing intervals following successful initial treatment.